MY138680A - N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors - Google Patents

N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Info

Publication number
MY138680A
MY138680A MYPI20042517A MYPI20042517A MY138680A MY 138680 A MY138680 A MY 138680A MY PI20042517 A MYPI20042517 A MY PI20042517A MY PI20042517 A MYPI20042517 A MY PI20042517A MY 138680 A MY138680 A MY 138680A
Authority
MY
Malaysia
Prior art keywords
ring
alkyl
aryl
sulfonylmethylalkyl
heteroaryl
Prior art date
Application number
MYPI20042517A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY138680(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY138680A publication Critical patent/MY138680A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20042517A 2003-06-27 2004-06-25 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors MY138680A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
MY138680A true MY138680A (en) 2009-07-31

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20042517A MY138680A (en) 2003-06-27 2004-06-25 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Country Status (33)

Country Link
US (1) US7485644B2 (enExample)
EP (1) EP1644340B1 (enExample)
JP (1) JP4701167B2 (enExample)
KR (1) KR20060026440A (enExample)
CN (2) CN1812974B (enExample)
AR (1) AR044931A1 (enExample)
AT (1) ATE414063T1 (enExample)
AU (1) AU2004251104B2 (enExample)
BR (1) BRPI0411929A (enExample)
CA (1) CA2529468A1 (enExample)
CO (1) CO5650254A2 (enExample)
CY (1) CY1108757T1 (enExample)
DE (1) DE602004017733D1 (enExample)
DK (1) DK1644340T3 (enExample)
ES (1) ES2315675T3 (enExample)
HR (1) HRP20090009T3 (enExample)
IL (1) IL172615A0 (enExample)
IS (1) IS8257A (enExample)
MX (1) MXPA05013460A (enExample)
MY (1) MY138680A (enExample)
NO (1) NO20060444L (enExample)
NZ (1) NZ544208A (enExample)
PL (1) PL1644340T3 (enExample)
PT (1) PT1644340E (enExample)
RU (1) RU2351595C2 (enExample)
SA (1) SA04250224B1 (enExample)
SE (1) SE0301922D0 (enExample)
SI (1) SI1644340T1 (enExample)
TW (1) TW200524898A (enExample)
UA (1) UA81491C2 (enExample)
UY (1) UY28387A1 (enExample)
WO (1) WO2005000822A1 (enExample)
ZA (1) ZA200510458B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
EP1951674B1 (en) * 2005-10-26 2011-11-23 Merck Serono SA Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2012005229A1 (ja) * 2010-07-08 2012-01-12 科研製薬株式会社 N-ヒドロキシホルムアミド誘導体およびそれを含有する医薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137146A0 (en) * 1998-01-30 2001-07-24 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
CN1159295C (zh) * 1999-06-04 2004-07-28 阿斯特拉曾尼卡有限公司 金属蛋白酶抑制剂
AU783284B2 (en) 2000-02-21 2005-10-13 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003091247A2 (en) * 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2004249496A1 (en) * 2003-06-19 2004-12-29 Ucb Pharma S.A. Hydroxamate sulfonamides as CD23 shedding inhibitors

Also Published As

Publication number Publication date
JP4701167B2 (ja) 2011-06-15
TW200524898A (en) 2005-08-01
DK1644340T3 (da) 2009-02-02
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
SI1644340T1 (sl) 2009-02-28
UA81491C2 (en) 2008-01-10
ATE414063T1 (de) 2008-11-15
CY1108757T1 (el) 2014-04-09
DE602004017733D1 (de) 2008-12-24
AU2004251104B2 (en) 2008-05-08
CN1812974A (zh) 2006-08-02
IL172615A0 (en) 2006-04-10
PL1644340T3 (pl) 2009-04-30
US20070197542A1 (en) 2007-08-23
RU2005141058A (ru) 2006-07-27
MXPA05013460A (es) 2006-03-09
KR20060026440A (ko) 2006-03-23
CN1812974B (zh) 2011-06-29
IS8257A (is) 2006-01-23
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
ES2315675T3 (es) 2009-04-01
EP1644340A1 (en) 2006-04-12
SE0301922D0 (sv) 2003-06-27
UY28387A1 (es) 2005-01-31
CO5650254A2 (es) 2006-06-30
EP1644340B1 (en) 2008-11-12
AR044931A1 (es) 2005-10-12
AU2004251104A1 (en) 2005-01-06
WO2005000822A1 (en) 2005-01-06
JP2007516164A (ja) 2007-06-21
PT1644340E (pt) 2009-01-02
CA2529468A1 (en) 2005-01-06
US7485644B2 (en) 2009-02-03
RU2351595C2 (ru) 2009-04-10
HRP20090009T3 (en) 2009-02-28
BRPI0411929A (pt) 2006-08-15
HK1086835A1 (en) 2006-09-29
CN102229589A (zh) 2011-11-02

Similar Documents

Publication Publication Date Title
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
SE0400284D0 (sv) Novel compounds
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
DK1052254T3 (da) Nitrogen-holdig heterocykliske derivater og medicin deraf
TW200635585A (en) Monocyclic substituted methanones
RU2007110629A (ru) Ингибиторы днк-пк
ES524236A0 (es) Un procedimiento para la preparacion de 1,4-dihidropiridina
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
SE9703377D0 (sv) New compounds
TW200612920A (en) Novel imidazolidine derivatives
CY1109085T1 (el) Νεα αλατα
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
CY1108757T1 (el) Ενωσεις ν-{'4-υποκατεστημενη πιπεραζινη-1-σουλφονυλμεθυλαλκυλ}-ν-υδροξυφορμαμιδιου ως αναστολεις της μεταλλοπρωτεϊνασης.
EA200101204A1 (ru) Новые бициклические соединения аминопиразинона, способ их получения и содержащие их фармацевтические композиции
NO20055657L (no) Nye bioisostaererav aktinonin
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
JP2007515383A5 (enExample)
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
NO20026004D0 (no) Nye podofyllotoksinkarbamat- og tiokarbamatforbindelser, fremgangsmåte vedderes fremstilling og farmasöytiske sammensetninger inneholdendedem